What Is Menaquinone-7 and What Are Its Benefits?

Menaquinone-7, usually shortened to MK-7, is a specific form of vitamin K2 found mainly in fermented foods. It has drawn attention over the past two decades because of its unusually long half-life in the bloodstream and a growing stack of research linking it to bone, cardiovascular, and metabolic benefits. The science is genuinely interesting in some areas and genuinely thin in others, and the gap between the two is worth understanding before you spend money on a supplement.

How MK-7 Differs From Other Forms of Vitamin K

Vitamin K is not a single molecule. It comes in two main natural families: vitamin K1, also called phylloquinone, which you get from leafy green vegetables, and vitamin K2, a group of compounds called menaquinones. The menaquinones are labeled by the length of their side chain, so MK-4 has four units, MK-7 has seven, and so on up to MK-13. MK-4 is found in animal products like eggs, meat, and liver. Longer-chain forms like MK-7, MK-8, and MK-9 show up in fermented foods such as cheese, curd, and sauerkraut.¹

What makes MK-7 stand out is how long it sticks around. MK-4 has a short serum half-life and produces a small area under the curve compared to vitamin K1, meaning it gets cleared from the blood quickly. Longer-chain menaquinones like MK-9 display a much longer serum half-life.² MK-7 follows this same pattern. Circulating levels remain elevated at least 24 hours after a single dose, and the compound shows a dose-response relationship, meaning higher intakes produce proportionally higher blood levels.³ That longer half-life and higher bioavailability give MK-7 more time to reach tissues outside the liver, including bone and blood-vessel walls, where vitamin K-dependent proteins do their work.⁴

There is also a practical note on how you take it. MK-7 in soft-gel capsules with an oily matrix reaches peak blood levels in about two to four hours, while compressed tablets take closer to six hours. The fat-soluble molecule dissolves faster when it is already in oil.³ If you take a tablet form, having it with a meal that includes some dietary fat will help.

Where to Find MK-7 in Food

By far the richest dietary source of MK-7 is natto, a traditional Japanese food made from soybeans fermented with Bacillus subtilis natto. Natto contains so much MK-7 that it accounts for large regional differences in blood levels within Japan itself. People in eastern Japan, around Tokyo, eat natto frequently and have markedly higher serum MK-7 concentrations than people in western Japan, around Hiroshima, where natto is rarely consumed.⁵ A single serving of natto can deliver several hundred micrograms of MK-7, an amount that dwarfs what you would get from other fermented foods.

Other sources include certain aged cheeses, sauerkraut, and fermented dairy products, but the MK-7 content is much lower. Most Western diets provide very little MK-7, which is one reason supplementation has become popular. If you have tried natto and can tolerate its famously sticky, pungent character, eating it a few times a week is the simplest way to maintain high MK-7 status without a pill. For everyone else, supplements are the practical route.

Bone Health

All forms of vitamin K serve as a cofactor for an enzyme that activates certain proteins by adding a chemical group to them, a process called gamma-carboxylation. In bone tissue, the key protein is osteocalcin. When osteocalcin is fully carboxylated, it binds calcium and helps incorporate it into bone mineral. When it is undercarboxylated, it cannot do this job properly. The ratio of carboxylated to undercarboxylated osteocalcin in your blood is used as a marker of your vitamin K status, and higher ratios generally reflect better bone metabolism.

MK-7 supplementation consistently shifts this ratio in the right direction. A double-blind trial found that daily doses of 100 micrograms or more significantly increased the carboxylated-to-undercarboxylated osteocalcin ratio and lowered undercarboxylated osteocalcin levels compared to placebo.⁶ A meta-analysis of Japanese studies echoed this: habitual natto eaters showed higher carboxylated osteocalcin and significantly lower undercarboxylated osteocalcin than non-consumers, though the overall certainty of evidence was rated low because the studies were observational.⁷

Translating that biochemical improvement into actual bone density gains has been harder to nail down. The most cited long-term trial, which ran for three years in healthy postmenopausal women, found that MK-7 supplementation slowed the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck, and favorably affected bone strength. It did not, however, improve density at the total hip.⁸ A broader review of high-dose vitamin K supplementation, including both K1 and K2 forms, concluded that fracture incidence in postmenopausal women was reduced and bone-strength indices improved, even when bone mineral density itself showed only modest increases.⁹

The overall picture is that MK-7 reliably improves the biochemical markers, modestly protects bone density at certain sites, and may reduce fracture risk. But a separate review cautioned that the evidence for vitamin K supplements increasing bone density and reducing fractures in people with osteoporosis is not yet strong enough to be considered definitive.¹⁰ If you already have osteoporosis, MK-7 is reasonable as an add-on but should not replace established therapies.

Arterial Stiffness and Cardiovascular Health

The same carboxylation process that activates osteocalcin in bone also activates a protein called matrix Gla protein (MGP) in blood-vessel walls. Fully activated MGP inhibits calcium from depositing in arterial tissue, and when vitamin K status is poor, inactive MGP accumulates and arteries gradually stiffen and calcify. One of the strongest mechanistic arguments for MK-7 supplementation is that it could keep MGP active and arteries flexible.

A 12-week trial tested this directly. At doses of 180 and 360 micrograms per day, MK-7 reduced circulating levels of inactive MGP by about 31% and 46% respectively, while placebo had no effect.¹¹ That is a clear sign the supplement was doing its biochemical job. The follow-up question is whether turning on MGP actually translates to softer arteries and fewer cardiovascular events.

A three-year trial in healthy postmenopausal women found that it can. MK-7 supplementation significantly decreased carotid-femoral pulse wave velocity, a gold-standard measure of arterial stiffness, and the benefit was most pronounced in women who started with stiffer arteries. Inactive MGP dropped by about half compared to placebo.¹² This is encouraging, but it is worth noting the population: healthy women with age-related stiffening, not patients with established cardiovascular disease.

Why Results in Kidney Disease Have Been Disappointing

If MK-7 activates MGP and MGP prevents arterial calcification, you would expect the biggest payoff in people at the highest risk for vascular calcification. Patients with chronic kidney disease, especially those on hemodialysis, develop severe arterial calcification and are profoundly vitamin K deficient. On paper, they are the ideal population for MK-7 supplementation.

MK-7 does reduce inactive MGP in these patients. High-dose supplementation can potently lower circulating levels of the inactive form.¹³ But despite that compelling biochemical signal, several randomized controlled trials in people with advanced kidney disease have failed to confirm cardiovascular benefits.¹³ An 18-month trial in hemodialysis patients found that coronary artery calcium scores trended slightly lower in the vitamin K group, but the difference was not statistically significant.¹⁴

There is one bright spot. A multicenter trial in hemodialysis patients did not find an overall benefit from MK-7 on arterial stiffness, but in the subgroup of patients with diabetes, MK-7 significantly decreased pulse wave velocity and dramatically slowed arterial stiffness progression compared to controls.¹⁵ That subgroup finding is intriguing but needs replication before anyone treats it as settled.

The disconnect between biochemistry and clinical outcomes in kidney disease is one of the most honest lessons in MK-7 research. Activating a protein is not the same as reversing years of calcification already cemented into arterial walls. Prevention and treatment are different challenges, and MK-7 may be more useful as the former.

Joint Health and Osteoarthritis

The same matrix Gla protein that protects arteries from calcification also operates in cartilage. When MGP is not properly activated due to low vitamin K status, calcium can deposit in cartilage and soft tissues around joints, contributing to osteoarthritis progression.¹⁶ This is a mechanistically coherent story: if vitamin K activates the proteins that keep calcium out of places it should not be, then deficiency could allow abnormal calcification in both arteries and joints.

Animal research has expanded the picture beyond simple calcification. An experimental study in rodents with knee osteoarthritis found that vitamin K2 may reduce cartilage damage through multiple pathways, including protecting against a form of cell death called ferroptosis, limiting tissue-degrading enzymes, and enhancing the activity of both MGP and another vitamin K-dependent protein called Gla-rich protein.¹⁷ The results are promising, but this is still preclinical work. No large human trials have yet tested MK-7 specifically for osteoarthritis outcomes. It is an area to watch rather than an area with firm answers.

Blood Sugar and Metabolic Effects

A more recent and somewhat surprising line of research connects MK-7 to blood sugar regulation. A trial in people with type 2 diabetes found that MK-7 supplementation led to roughly a 13% reduction in fasting blood glucose, a 28% drop in fasting insulin, and about a 7% decrease in hemoglobin A1c. The researchers also observed significant improvements in glucose tolerance in diet-induced obese mice.¹⁸ The study proposed that part of the mechanism involves shifts in the gut microbiome and its metabolic outputs, adding a layer of complexity beyond the classical vitamin K carboxylation pathway.

Those effect sizes, particularly the nearly 30% drop in fasting insulin, are large enough to raise eyebrows. If they replicate across multiple independent trials, MK-7 could become a meaningful adjunct for managing insulin resistance. For now, this remains a single study, and a healthy skepticism is warranted until larger confirmatory trials are published. The direction of the finding, though, is consistent with observational data linking higher vitamin K intake to lower diabetes risk.

Emerging Research on Brain Health

A newer thread of research suggests that MK-7 could matter for cognitive function in aging. The proposed mechanism ties back to its arterial effects: by mitigating calcification and stiffness in the blood vessels that supply the brain, MK-7 might help preserve cerebral blood flow and protect against cognitive decline. A 2024 review noted that a growing body of observational and interventional evidence supports the idea that vitamin K2 plays a role in linking vascular health to brain health, potentially helping to prevent cognitive impairment in older populations.¹⁹ This is plausible biology, but it is early-stage. No randomized trial has yet shown that MK-7 supplementation improves cognitive outcomes. It is more of a hypothesis with supportive pieces than a proven benefit.

Safety, Drug Interactions, and Dosing

MK-7 has an unusually clean safety profile. The lack of reported adverse effects in healthy people has led multiple regulatory bodies, including the U.S. Institute of Medicine, the European Commission, and the WHO, to decline to set a formal tolerable upper intake level for any form of vitamin K. The UK Expert Vitamins and Minerals group has recommended a guidance level of 1,000 micrograms per day, and the Council for Responsible Nutrition set a supplement-specific upper level at 10,000 micrograms per day.²⁰ For context, most commercially available MK-7 supplements contain between 100 and 200 micrograms per capsule, well within any proposed limit.

There is one major exception to this reassuring safety picture, and it is serious enough to flag clearly: if you take a vitamin K antagonist anticoagulant such as warfarin, MK-7 supplements can directly interfere with the drug’s action. These medications work by blocking vitamin K’s role in clotting. Adding MK-7 pushes the balance back toward clotting and can destabilize your anticoagulant control. A study in healthy volunteers found that MK-7 doses as low as 10 micrograms, far less than any retail supplement dose, significantly altered anticoagulation sensitivity in some individuals.²¹ The recommendation from the researchers was unambiguous: people on vitamin K antagonist therapy should avoid MK-7 supplements entirely.

This warning applies specifically to vitamin K antagonists like warfarin and acenocoumarol. Newer direct oral anticoagulants like apixaban and rivarelbaan work through a different mechanism and are not affected by vitamin K intake. If you are on any blood thinner and are unsure which type, check with your prescriber before starting MK-7.

Whether Gut Bacteria Supply Enough Vitamin K

You may have read that gut bacteria produce menaquinones, which is true. Certain species in your intestinal tract synthesize various forms of vitamin K2 as part of their normal metabolism, and fecal menaquinone profiles differ depending on the composition of a person’s microbiome.²² This has led to a persistent assumption that the bacteria living in your gut provide a meaningful backup supply of vitamin K2.

The evidence suggests otherwise. While gut bacteria do produce menaquinones in high concentrations within the intestine, very little of it actually reaches your bloodstream. Menaquinones were not detectable in circulation in the same study that found abundant fecal concentrations, consistent with broader evidence that bacterially produced vitamin K2 is poorly absorbed.²² Mouse research has shown that dietary vitamin K can be remodeled into bacterial menaquinone forms by gut microbes, but isolated human gut microbes could only convert the vitamin K precursor menadione, not intact vitamin K molecules, into menaquinones.²³

The practical upshot is that you cannot count on your gut bacteria to keep your vitamin K2 status adequate. Your MK-7 supply comes from what you eat or supplement, not from what your microbiome produces internally. This is one of those areas where a plausible-sounding idea, that gut bacteria can cover for dietary shortfalls, does not hold up under measurement.

How MK-7 Supplements Are Made

Most commercial MK-7 is produced by fermenting soybeans or other substrates with Bacillus subtilis natto, the same bacterium responsible for making natto. The process essentially mimics what happens in traditional natto production, but under controlled industrial conditions optimized to maximize MK-7 output.²⁴ The organism is considered safe for food use, and its genetics are well characterized, making it a favored workhorse for scaled-up production.

Yields have historically been limited by the bacterium’s tendency to die off during fermentation, but recent bioengineering strategies have made substantial progress. One approach combined soy protein hydrolysate with an emulsifier to extend the bacterium’s lifespan during fermentation, increasing MK-7 yields by more than five-fold compared to a standard growth medium.²⁵ These advances matter for consumers because higher production efficiency tends to bring down supplement costs over time. Some newer MK-7 products use synthetic or semi-synthetic routes, but fermentation-derived MK-7 remains the dominant form on the market and the form used in most clinical trials.

One detail worth noting: because MK-7 is fat-soluble and somewhat unstable when exposed to light and heat, supplement quality can vary. Products formulated in oil-based soft gels and stored in opaque packaging tend to preserve the active molecule better than those in transparent bottles or dry tablet forms. If your supplement has been sitting on a bright shelf for months, its actual MK-7 content may be lower than what the label claims.

1
PubMed Central. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women
2
PubMed Central. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women – Section: Discussion
3
Longdom Publishing. Pharmacokinetics of Menaquinone-7 (Vitamin K2) in Healthy Volunteers
4
PubMed Central. MK-7 and Its Effects on Bone Quality and Strength
5
PubMed. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2
6
PubMed. Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials
7
PubMed Central. Habitual natto intake elevates serum MK-7 levels, enhances osteocalcin carboxylation, and supports bone density: a meta-analysis of Japanese evidence
8
PubMed. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
9
PubMed. High-dose vitamin K supplementation reduces fracture incidence in postmenopausal women: a review of the literature
10
PubMed Central. Influence of Vitamin K on Bone Mineral Density and Osteoporosis
11
PubMed. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein
12
PubMed. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial
13
PubMed. Vitamin K and cardiovascular complications in chronic kidney disease patients
14
Kidney International Reports. Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K (Trevasc-HDK): A Randomized Controlled Trial
15
PubMed Central. Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial
16
PubMed Central. The Relationship between Vitamin K and Osteoarthritis: A Review of Current Evidence
17
PubMed Central. Efficacy of Oral Vitamin K2 Supplementation in Experimental Knee Osteoarthritis
18
BMC Medicine. Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites
19
PubMed Central. The role of vitamin K2 in cognitive impairment: linking vascular health to brain health
20
Scientific Reports. Safety evaluation of vitamin K2 (menaquinone-7) via toxicological tests
21
PubMed. Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers
22
The American Journal of Clinical Nutrition. Fecal Menaquinone Profiles of Healthy Adults Are Associated with Gut Microbiota Composition
23
PubMed Central. Dietary vitamin K is remodeled by gut microbiota and influences community composition
24
PubMed Central. Metabolic Engineering Strategy for Bacillus subtilis Producing MK-7
25
PubMed Central. Combination of SPH and SP80 prolongs the lifespan of Bacillus subtilis natto to enhance industrial menaquinone-7 biosynthesis